Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

(2016) Thomas H. Langenickel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Unbelievable Folly of Clinical Trials in Heart Failure

(2016) Milton Packer   Circulation-Heart Failure

Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey

(2016) Michel Komajda et al.   EUROPEAN JOURNAL OF HEART FAILURE

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN JOURNAL OF HEART FAILURE

Valsartan/Sacubitril for Heart Failure

(2016) Arthur M. Feldman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trials and Tribulations

(2016) Jay N. Cohn   JOURNAL OF CARDIAC FAILURE

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

(2016) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sacubitril-Valsartan for the Treatment of Heart Failure

(2016) Daniel A. Ollendorf et al.   JAMA Internal Medicine

Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera

(2016) Milton Packer   JACC-Heart Failure

Are We Really in Love With Old Therapies?

(2016) Christopher M. O’Connor et al.   JACC-Heart Failure

Neprilysin Inhibition in the Time of Precision Medicine ∗

(2016) Arthur M. Feldman   JACC-Heart Failure

Combined Angiotensin Receptor/Neprilysin Inhibitors: A Review of the New Paradigm in the Management of Chronic Heart Failure

(2015) Peter S. Macdonald   CLINICAL THERAPEUTICS

Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?

(2015) N. Vodovar et al.   EUROPEAN HEART JOURNAL

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients

(2015) Akshay S. Desai et al.   EUROPEAN HEART JOURNAL

Eplerenone in chronic heart failure with depressed systolic function

(2015) Maurizio Volterrani et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis

(2015) R. Ye et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial

(2015) Orly Vardeny et al.   JOURNAL OF CARDIAC FAILURE

The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure

(2015) Eugene Braunwald   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

(2015) Brian Claggett et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

(2013) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer’s Disease

(2013) Said AbdAlla et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

2013 ACCF/AHA Guideline for the Management of Heart Failure

(2013) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

(2013) Jean-Charles Lambert et al.   NATURE GENETICS

APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38

(2012) Maria Luisa Moro et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease

(2011) Yi-Fei Dong et al.   FASEB JOURNAL

Dual-Acting Angiotensin Receptor–Neprilysin Inhibition

(2010) Julian Segura et al.   CURRENT HYPERTENSION REPORTS

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

(2010) Karl Swedberg et al.   LANCET

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

(2009) Albert Fournier et al.   Expert Review of Neurotherapeutics

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

(2009) Marvin A Konstam et al.   LANCET